Displaying drugs 1 - 25 of 647 in total
Bevacizumab
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Synonyms: … Anti-VEGF monoclonal antibody ... Anti-VEGF Humanized Monoclonal Antibody …
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Vascular Endothelial Growth Factor-directed Antibody Interactions …
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Vascular Endothelial Growth Factor-directed Antibody Interactions …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Synonyms: … Humanised anti-IL-6 receptor monoclonal antibody …
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive ... formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody …
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive ... formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody …
Sutimlimab
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Synonyms: … Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s …
Matched Description: … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which …
Matched Description: … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Synonyms: … Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853 …
Matched Description: … [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Matched Categories: … Antibody-drug Conjugates …
Matched Description: … [A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1. ... Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody ... [A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed …
Matched Categories: … Antibody-drug Conjugates …
Digoxin Immune Fab (Ovine)
Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Approved
Matched Synonyms: … Digoxin-specific Antibody Fragments …
Matched Description: … Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative …
Matched Description: … Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative …
Dinutuximab
Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Matched Synonyms: … Monoclonal antibody ch14.18 ... CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO) …
Matched Description: … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed ... By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent …
Matched Categories: … Glycolipid Disialoganglioside-directed Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Glycolipid Disialoganglioside-directed Antibody Interactions …
Matched Description: … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed ... By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent …
Matched Categories: … Glycolipid Disialoganglioside-directed Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Glycolipid Disialoganglioside-directed Antibody Interactions …
Elranatamab
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Synonyms: … ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135 ... B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB …
Matched Description: … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs ... The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. …
Matched Description: … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs ... The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. …
Polatuzumab vedotin
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E ... [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Matched Categories: … Antibody-drug Conjugates ... CD79b-directed Antibody–Drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Antibody-drug Conjugates ... CD79b-directed Antibody–Drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Elotuzumab
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. ... Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide ... Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted …
Matched Categories: … SLAMF7-directed Antibody Interactions ... SLAMF7-directed Immunostimulatory Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … SLAMF7-directed Antibody Interactions ... SLAMF7-directed Immunostimulatory Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Atezolizumab
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Dostarlimab
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Matched Categories: … Programmed Death Receptor-1 Blocking Antibody ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1-directed Antibody Interactions …
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. …
Matched Categories: … CD11a-directed Antibody Interactions ... CD11a-directed Humanized IgG1 Antibody …
Matched Categories: … CD11a-directed Antibody Interactions ... CD11a-directed Humanized IgG1 Antibody …
Denosumab
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear …
Obiltoxaximab
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Approved
Matched Description: … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of ... Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis …
Matched Categories: … Anthrax Protective Antigen-directed Antibody ... Anthrax Protective Antigen-directed Antibody Interactions …
Matched Categories: … Anthrax Protective Antigen-directed Antibody ... Anthrax Protective Antigen-directed Antibody Interactions …
Galcanezumab
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used ... [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Matched Categories: … Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody …
Rozanolixizumab
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody ... positive for the anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody …
Sacituzumab govitecan
Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent ... sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Antibody-drug Conjugates ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese …
Abatacept
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Categories: … CD80-directed Antibody Interactions ... CD86-directed Antibody Interactions …
Zilucoplan
Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Etanercept
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1....
Approved
Investigational
Eculizumab
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Description: … Eculizumab is a monoclonal antibody that targets complement protein C5. …
Displaying drugs 1 - 25 of 647 in total